Regulating TRAIL Receptor-Induced Cell Death at the Membrane: A Deadly Discussion

Author(s): Sarah Shirley, Alexandre Morizot, Olivier Micheau

Journal Name: Recent Patents on Anti-Cancer Drug Discovery

Volume 6 , Issue 3 , 2011

Become EABM
Become Reviewer
Call for Editor


The use of TRAIL/APO2L and monoclonal antibodies targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature review aims to present and highlight recent findings of the deadly discussion that determines tumor cell fate upon TRAIL engagement.

Keywords: chemotherapy, death domain, death effector domain, DISC, FADD, c-FLIP,, scaffold, TRAIL, TRAIL-R4, APO2-L

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [311 - 323]
Pages: 13
DOI: 10.2174/157489211796957757

Article Metrics

PDF: 37